Armis Launches Armis Centrix™, the AI-powered Cyber Exposure Management Platform
13.9.2023 15:00:00 EEST | Business Wire | Press release
Armis, the asset intelligence cybersecurity company, today announced the launch of Armis Centrix™, the AI-powered cyber exposure management platform. Armis Centrix™ is a seamless, frictionless, cloud-based platform that proactively secures all your assets, remediates vulnerabilities, blocks threats and protects your entire attack surface.
Armis Centrix™ enables organizations to discover, contextualize, enrich and profile every asset in their environment whilst also building a line of defense by leveraging Armis Centrix™ Asset Intelligence risk scores, policies, alerting and visualizations and most importantly: prioritize efforts against the exposures that matter to your business. Armis Centrix™ also integrates with existing enforcement and ticketing tools to establish end-to-end workflows and true risk lifecycle management and track risk reduction efforts to easily report on progress made. Armis Centrix™ takes proactive measures, detects threats & stops attacks to establish operational workflows and track risk reduction.
“In a perimeter-less world, where assets are digitally connected, traditional cybersecurity boundaries no longer exist. Legacy on-premise systems and point solutions are no longer fit for purpose leaving your attack surface and most critical assets open and exposed to cyber criminals and multiple bad actors,” said Nadir Izrael, CTO and Co-Founder, Armis. “The sheer scale and dynamic nature of the attack surface necessitates an entirely different, AI-driven approach, and that’s what Armis Centrix™ is - the AI that powers a suite of powerful tools for managing cyber risk exposure.”
Armis Centrix™ helps organizations see, protect and manage their entire attack surface, continuously safeguarding their mission-critical assets from cyber threats. Born in the cloud and fueled by AI, only Armis Centrix™ delivers a true modular approach to cyber exposure management covering the most critical cybersecurity needs for our clients across 4 solutions:
- Asset management and security - Complete asset inventory of all asset types allowing any organization to see and secure the attack surface
- OT/IOT security - See and secure OT/IOT networks and physical assets, ensure uptime and build an effective & comprehensive security strategy
- Medical device security - Complete visibility and security for all medical devices, clinical assets and the entire healthcare ecosystem - with zero disruption to patient care
- Vulnerability prioritization and remediation - Consolidate, prioritize and remediate all vulnerabilities; improve mean time to remediation (MTTR) with automatic remediation and ticketing workflows
“This is a revolutionary advancement that will change the way in which companies answer key questions regarding their cybersecurity posture,” said Dana Gilboa, Chief Product Officer, Armis. “Armis can help organizations mitigate their cyber asset risks and protect the entire attack surface by providing the needed intelligence to align security and business efforts. With this approach, we can ultimately provide organizations with the peace of mind they need, allowing them to see, protect and manage all their critical assets.”
Armis Centrix™ is industry-agnostic, allowing Manufacturing, Health and Medical, Information Technology, Energy and Utilities, Financial Services, Transportation, Telecommunications and Media, Public Sector and many more to benefit from its capabilities. Additionally, Armis collaborates with the world’s premier global technology vendors to ensure its customers can seamlessly integrate the Armis Centrix™ platform with existing IT and security stacks.
If you would like to know more about Armis Centrix™, the cyber exposure management platform, visit armis.com/centrix or contact us at info@armis.com.
About Armis
Armis, the asset intelligence cybersecurity company, protects the entire attack surface and manages the organization's cyber risk exposure in real time. In a rapidly evolving, perimeter-less world Armis ensures that organizations continuously see, secure, protect and manage all critical assets. Armis secures Fortune 100, 200 and 500 companies as well as national governments, state and local entities to help keep critical infrastructure, economies and society safe and secure 24/7. Armis is a privately held company headquartered in California.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230913528020/en/
Contact information
Rebecca Cradick
Senior Director, Global Communications
Armis
pr@armis.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release
Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o
Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a
DAYBU ® (trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 13:49:00 EEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating condition," said Catherine Owen Adams, Acadia’s Chief Executive Officer. “Our commitment is to make a meaningful difference in the lives of patients, caregivers, and the wider Rett com
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 12:18:00 EEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 11:28:00 EEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
